PepGen Inc. (PEPG)
2.83
0.11 (4.04%)
At close: Jan 15, 2025, 2:30 PM
Company Description
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases.
The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD).
It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD.
The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
PepGen Inc.
| Country | United States |
| IPO Date | May 6, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 76 |
| CEO | Dr. James G. McArthur Ph.D. |
Contact Details
Address: 245 Main Street Cambridge, Massachusetts United States | |
| Website | https://www.pepgen.com |
Stock Details
| Ticker Symbol | PEPG |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001835597 |
| CUSIP Number | 713317105 |
| ISIN Number | US7133171055 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. James G. McArthur Ph.D. | President, Chief Executive Officer, Treasurer, Secretary & Director |
| Noel P. Donnelly M.B.A. | Chief Financial Officer |
| David E. Borah C.F.A., M.B.A. | Senior Vice President of IR & Corporate Communications |
| Dr. Afsaneh Mohebbi Ph.D. | Senior Vice President of Portfolio and Program Management |
| Dr. Hayley Parker Ph.D. | Senior Vice President of Global Regulatory Affairs |
| Dr. Michael Gait Ph.D. | Founder & Scientific Advisory Board Member |
| Dr. Michelle L. Mellion M.D. | Chief Medical Officer |
| Emiko Bryant | Chief of Staff |
| Mary Beth DeLena J.D. | General Counsel & Secretary |
| Niels Svenstrup Ph.D. | Senior Vice President of Biological Chemistry |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 16, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 07, 2024 | 10-Q | Quarterly Report |
| Nov 07, 2024 | 8-K | Current Report |
| Oct 08, 2024 | 8-K | Current Report |
| Sep 19, 2024 | 8-K | Current Report |
| Aug 20, 2024 | 4 | Filing |
| Aug 20, 2024 | 3 | Filing |